Clinical Trials Logo

Inflammation clinical trials

View clinical trials related to Inflammation.

Filter by:

NCT ID: NCT05792527 Recruiting - Clinical trials for Rheumatoid Arthritis

L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis

Start date: March 5, 2023
Phase: Phase 3
Study type: Interventional

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

NCT ID: NCT05792137 Recruiting - Inflammation Clinical Trials

Postprandial Monocyte Study

PPMS
Start date: November 14, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to determine the role of a type of immune cell in blood, called a non-classical monocytes (NCMs), following consumption of a high-fat meal. Previous studies have found that monocytes are important for blood vessel health. In this study, two different high-fat meals will be used to study the effect of different types of dietary fat on postprandial NCMs. The investigators will characterize NCMs in both fasting conditions and following consumption of two different high-fat meals, and will evaluate whether the type of fat in a meal affects NCMs in blood.

NCT ID: NCT05791695 Completed - Clinical trials for Intraocular Inflammation

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

Start date: September 16, 2022
Phase:
Study type: Observational

Specific study objectives include: - To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually). - To estimate the annual and quarterly incidence of intraocular inflammation (IOI) and suspected endophthalmitis for aflibercept user injections by aflibercept dispensing device. Secondary objectives • To estimate the annual incidence of IOI and suspected endophthalmitis for aflibercept user injections by dispensing device, stratified by indication for use, history of IOI, and provider characteristics.

NCT ID: NCT05791617 Recruiting - Stroke Clinical Trials

PET/MR in Post Stroke Cardiac Inflammation Study

PEPSI
Start date: July 1, 2023
Phase:
Study type: Observational

Patients with stroke have a 25x higher risk of cardiovascular complications within the first 30 days of the event compared to individuals without stroke. The mechanisms behind these complications are not well understood. Evidence suggests that inflammation plays a central role. With the present proof-of-concept prospective cohort study, the investigators aim to demonstrate that patients develop cardiac inflammation after stroke by performing positron emission tomography (PET) magnetic resonance imaging (MRI) of the heart within 15 days after stroke. As a secondary aim, the investigators will evaluate whether post-stroke cardiac inflammation persists at 3 months after stroke. The control group will be comprised of age- and sex-matched individuals without stroke.

NCT ID: NCT05791370 Completed - Healthy Clinical Trials

Red Palm Olein on Inflammation and Gut Health

RPO
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

A parallel intervention was conducted to test the effect of consuming diets enriched with red palm olein (RPOO), extra virgin coconut oil (EVCO) and extra virgin olive oil (EVOO; positive control) in centrally obese individuals over a 12-week period. Following the screening of the subjects' health status, including their biochemical and lipid profiles, the subjects completed a 12-week dietary intervention. Both fasting blood and urine samples were collected at baseline (day 0) and endpoint (week 12); measurements were taken in duplicates. All data collected were blinded to the investigators by an independent third party until the completion of the analysis.

NCT ID: NCT05790564 Recruiting - Metabolic Syndrome Clinical Trials

Almonds to Improve Gut Health and Decrease Inflammation

Start date: November 17, 2022
Phase: N/A
Study type: Interventional

Almonds are a good source of beneficial compounds. This study will investigate if eating almonds everyday for 12 weeks can affect gut health and inflammation in persons with metabolic syndrome. Investigators will measure changes in metabolism, heart health, and the levels of vitamins and other compounds from almonds.

NCT ID: NCT05788601 Active, not recruiting - Obesity Clinical Trials

Dapiglutide for the Treatment of Obesity

DREAM
Start date: April 27, 2023
Phase: Phase 2
Study type: Interventional

This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly. The study will investigate the efficacy of once-weekly subcutaneously administered of 4 mg and 6 mg dapiglutide versus placebo in 54 obese individuals (BMI >30 kg/m2) during a 12-week treatment period.

NCT ID: NCT05787678 Recruiting - Clinical trials for Asthma; Eosinophilic

Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion

DEBORA
Start date: October 1, 2023
Phase:
Study type: Observational

Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics (small airway dysfunction and mucin production) in uncontrolled severe asthma patients in the real life setting without control group

NCT ID: NCT05786820 Recruiting - Periodontitis Clinical Trials

Impact of Pycnogenol® on Gingival Inflammation

PINEGIN
Start date: March 17, 2022
Phase: N/A
Study type: Interventional

This randomized, double-blind, placebo-controlled 2-arm, parallel group clinical trial is designed to evaluate the impact of the regular consumption of a polyphenol-containing Maritime Pine (Pinus pinaster) bark extract (Pycnogenol®) on clinical signs of gingival inflammation in a cohort of periodontal aftercare patients

NCT ID: NCT05782010 Recruiting - Clinical trials for Gastrointestinal Diseases

SCI-Pex Study - Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids

SCI-Pex
Start date: June 15, 2023
Phase: N/A
Study type: Interventional

The SCI-Pex study is a multicenter, prospective, non-controlled investigation on PexyEazy®, a new device for treatment of hemorrhoids based on the mucopexy method. Mucopexy is a well established method where sutures are applied above the hemorrhoids. When knots are tied, the hemorrhoids are lifted inwards to their normal position, which makes them swell down and symptoms disappears. PexyEazy® perform a mukopexy in a semiautomatic, faster and easier way on awake patient in less than 10 minutes. The SCI-Pex study will evaluate the safety and performance of PexyEazy on 35 patients with hemorrhoids grade II and III with a follow-up after 1 week, 3 months and 5 years. Adverse events, pain and other complications will be recorded, quality of life and hemorrhoid symptom questionnaires and clinical examination after 3 months will be monitored to evaluate the result after a PexyEazy® procedure.